Cover Image
市場調查報告書

遺傳性血管水腫(HAE):開發平台分析

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 200958
出版日期 內容資訊 英文 94 Pages
訂單完成後即時交付
價格
Back to Top
遺傳性血管水腫(HAE):開發平台分析 Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2016
出版日期: 2016年06月08日 內容資訊: 英文 94 Pages
簡介

所謂遺傳性血管水腫(HAE)是人體組織各處(腹部、臉部等)產生許多朣塊這樣的先天性絕症。主要症狀有劇烈的腹痛及肌肉痙攣、脫水症狀、腹瀉·休克症、聲音嘶啞、吞嚥困難·呼吸困難等。主要治療法為藥物療法(Epinephrine·抗組織胺藥物·皮質類固醇其他)等。

本報告提供全球各國的遺傳性血管水腫(HAE)所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查。

目錄

簡介

  • 分析範圍

遺傳性血管水腫概要

治療藥的開發

  • 遺傳性血管水腫開發中產品:概要
  • 遺傳性血管水腫開發中產品:比較分析

各企業正在開發的遺傳性血管水腫治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

遺傳性血管水腫治療藥:開發中的產品一覽(各企業)

遺傳性血管水腫開發治療藥的企業

  • Adverum Biotechnologies, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Cevec Pharmaceuticals GmbH
  • CSL Limited
  • Global Blood Therapeutics, Inc.
  • iBio, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Pharming Group N.V.
  • ProMetic Life Sciences Inc.
  • Ra Pharmaceuticals, Inc.
  • Shire Plc

遺傳性血管水腫:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

遺傳性血管水腫治療藥:開發中產品的最新趨勢

遺傳性血管水腫相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8183IDB

Summary

Global Markets Direct's, 'Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2016', provides an overview of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)
  • The report reviews pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) therapeutics and enlists all their major and minor projects
  • The report assesses Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Overview
  • Therapeutics Development
    • Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics under Development by Companies
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Products under Development by Companies
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies Involved in Therapeutics Development
    • Adverum Biotechnologies, Inc.
    • Arrowhead Pharmaceuticals, Inc.
    • BioCryst Pharmaceuticals, Inc.
    • Cevec Pharmaceuticals GmbH
    • CSL Limited
    • Global Blood Therapeutics, Inc.
    • iBio, Inc.
    • Ionis Pharmaceuticals, Inc.
    • Pharming Group N.V.
    • ProMetic Life Sciences Inc.
    • Ra Pharmaceuticals, Inc.
    • Shire Plc
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ANN-002 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ARCF-12 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • avoralstat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BCX-7353 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BEL-0215 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C1 esterase inhibitor (human) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C1 esterase inhibitor (human) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C1 esterase inhibitor (human) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C1 esterase inhibitor (recombinant) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C1 esterase inhibitor (recombinant) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CSL-312 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GBT-18713 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • icatibant acetate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IONIS-PKKRx - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lanadelumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SHP-623 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Plasma Kallikrein for DME and HAE - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide to Inhibit Kallikrein for Hereditary Angioedema - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Recent Pipeline Updates
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Product Development Milestones
    • Featured News & Press Releases
      • May 19, 2016: KalVista Pharmaceuticals to Support Global Conference Focused on Hereditary Angioedema
      • Apr 07, 2016: Pharming Announces Adoption By The European Commission Of The CHMP Recommendation To Change The Terms Of The Marketing Authorisation For Ruconest
      • Mar 23, 2016: CINRYZE (C1 inhibitor [human]) now available in Canada
      • Feb 26, 2016: Pharming Announces Positive CHMP Opinion To Change The Terms Of The Marketing Authorisation For Ruconest
      • Feb 09, 2016: Pharming And Cytobioteck Announce Extension Of Distribution Agreement For Ruconest
      • Feb 08, 2016: BioCryst Announces Results From OPuS-2
      • Jan 06, 2016: Pharming Announces Completion Of Patient Enrolment In Clinical Study Of Ruconest For Prophylaxis Of Hereditary Angioedema
      • Dec 21, 2015: Pharming And Hyupjin Announce Receipt Of The South Korean Marketing Authorisation For Ruconest
      • Dec 07, 2015: European Medicines Agency Reaffirms Important Health Benefits and Safety of RUCONEST for Patients With Hereditary Angio-edema
      • Nov 09, 2015: Dyax Presents Phase 1b DX-2930 Data at the American College of Allergy, Asthma, and Immunology Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Adverum Biotechnologies, Inc., H1 2016
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Arrowhead Pharmaceuticals, Inc., H1 2016
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by BioCryst Pharmaceuticals, Inc., H1 2016
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Cevec Pharmaceuticals GmbH, H1 2016
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by CSL Limited, H1 2016
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Global Blood Therapeutics, Inc., H1 2016
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by iBio, Inc., H1 2016
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Ionis Pharmaceuticals, Inc., H1 2016
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Pharming Group N.V., H1 2016
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by ProMetic Life Sciences Inc., H1 2016
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Ra Pharmaceuticals, Inc., H1 2016
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Shire Plc, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics - Recent Pipeline Updates, H1 2016

List of Figures

  • Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top